Kyowa Hakko Released Mid-Term Business Plan For 2008-2010
This article was originally published in PharmAsia News
Kyowa Hakko released its mid-term business plan for fiscal years 2008-2010. Based on the integration of Kyowa Hakko and Kirin Pharma, the plan estimates net sales to reach ¥513 billion, with ¥73 billion in income before goodwill amortization and a 30+ percent dividend payout ratio by 2010. To maintain top class biopharma production, Kyowa Hakko plans to build a new antibody drug production facility inside its bio technology institute in Takasaki, Gunma Prefecture. The company also plans to build a new research facility inside the Tokyo Research Park. Total capital investment will be ¥83 billion. On the same day, Kyowa Hakko reported results for the past fiscal year ending March 31, with both sales (¥392 billion) and net income (¥23.4 billion) the highest in the company's history. (Click here for more - Japanese language
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.